- Home
- DLPN vs CLDI Comparison
DLPN vs CLDI Comparison
Compare DLPN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- CLDI
- Stock Information
- Founded
- DLPN 1996
- CLDI 2014
- Country
- DLPN United States
- CLDI United States
- Employees
- DLPN N/A
- CLDI N/A
- Industry
- DLPN Other Consumer Services
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLPN Consumer Discretionary
- CLDI Health Care
- Exchange
- DLPN Nasdaq
- CLDI Nasdaq
- Market Cap
- DLPN 12.3M
- CLDI 10.2M
- IPO Year
- DLPN N/A
- CLDI N/A
- Fundamental
- Price
- DLPN $1.27
- CLDI $0.66
- Analyst Decision
- DLPN Strong Buy
- CLDI
- Analyst Count
- DLPN 1
- CLDI 0
- Target Price
- DLPN $5.00
- CLDI N/A
- AVG Volume (30 Days)
- DLPN 31.7K
- CLDI 34.7M
- Earning Date
- DLPN 08-13-2025
- CLDI 08-12-2025
- Dividend Yield
- DLPN N/A
- CLDI N/A
- EPS Growth
- DLPN N/A
- CLDI N/A
- EPS
- DLPN N/A
- CLDI N/A
- Revenue
- DLPN $48,618,803.00
- CLDI N/A
- Revenue This Year
- DLPN $6.57
- CLDI N/A
- Revenue Next Year
- DLPN $18.10
- CLDI N/A
- P/E Ratio
- DLPN N/A
- CLDI N/A
- Revenue Growth
- DLPN 0.31
- CLDI N/A
- 52 Week Low
- DLPN $0.75
- CLDI $0.20
- 52 Week High
- DLPN $2.00
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- DLPN 65.72
- CLDI 82.55
- Support Level
- DLPN $1.07
- CLDI $0.23
- Resistance Level
- DLPN $1.39
- CLDI $0.25
- Average True Range (ATR)
- DLPN 0.08
- CLDI 0.10
- MACD
- DLPN 0.02
- CLDI 0.03
- Stochastic Oscillator
- DLPN 78.13
- CLDI 32.79
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.